Aadi Sub Company Profile

What is the competitive landscape for AADI SUB

AADI SUB has one approved drug.

There are seven US patents protecting AADI SUB drugs.

There are one hundred and thirty-eight patent family members on AADI SUB drugs in thirty-three countries and fourteen supplementary protection certificates in seven countries.

Summary for Aadi Sub

International Patents:	138
US Patents:	7
Tradenames:	1
Ingredients:	1
NDAs:	1

Drugs and US Patents for Aadi Sub

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Aadi Sub	FYARRO	sirolimus	POWDER;INTRAVENOUS	213312-001	Nov 22, 2021		RX	Yes	Yes	12,061,183		Y
Aadi Sub	FYARRO	sirolimus	POWDER;INTRAVENOUS	213312-001	Nov 22, 2021		RX	Yes	Yes	12,133,844
Aadi Sub	FYARRO	sirolimus	POWDER;INTRAVENOUS	213312-001	Nov 22, 2021		RX	Yes	Yes	10,705,070		Y
Aadi Sub	FYARRO	sirolimus	POWDER;INTRAVENOUS	213312-001	Nov 22, 2021		RX	Yes	Yes
Aadi Sub	FYARRO	sirolimus	POWDER;INTRAVENOUS	213312-001	Nov 22, 2021		RX	Yes	Yes	10,973,806
Aadi Sub	FYARRO	sirolimus	POWDER;INTRAVENOUS	213312-001	Nov 22, 2021		RX	Yes	Yes	10,206,887		Y

International Patents for Aadi Sub Drugs

Country	Patent Number	Estimated Expiration
Canada	2990693
Japan	6433371
Brazil	112022007710
Cyprus	1120548
World Intellectual Property Organization (WIPO)	2017004249
European Patent Office	4051241

Supplementary Protection Certificates for Aadi Sub Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0648494	01C0037	France		PRODUCT NAME: SIROLIMUS; NAT. REGISTRATION NO/DATE: EU/1/01/171/001-005 20010313; FIRST REGISTRATION: IKS55243 20000926
0763039	PA2008009	Lithuania		PRODUCT NAME: TEMSIROLIMUSUM; REG. NO/DATE: EU/1/07/424/001 20071119
0763039	122008000023	Germany		PRODUCT NAME: TEMSIROLIMUS ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/07/424/001 20071119
0648494	C300055	Netherlands		PRODUCT NAME: SIROLIMUS, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AAN- VAARDBAAR ZOUT; NATL. REGISTRATION NO/DATE: EU/1/01/171/001 - EU/1/01/171/005 20010313; FIRST REGISTRATION: CH CH/55243 20000926
0401747	SPC/GB01/036	United Kingdom		PRODUCT NAME: SIROLIMUS; REGISTERED: CH IKS 55243 20000926; UK EU/1/01/171/001-005 20010313
0763039	SPC/GB08/025	United Kingdom		PRODUCT NAME: TEMSIROLIMUS AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/07/424/001 20071119

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Aadi Sub

Aadi Sub Market Analysis and Financial Projection

Last updated: February 10, 2026

Summary

Aadi Biosciences Sub holds a specific position within the oncology pharmaceutical landscape. The company focuses primarily on targeted therapies for pancreatic and other solid tumors. Its pipeline largely comprises novel compounds with potential for combination therapies. Aadi exhibits moderate market penetration, supported by strategic collaborations and IP protections. Its strengths include a focused R&D approach, early-stage patent portfolio, and partnerships with academic institutions. However, its market influence remains limited by late-stage clinical trial progress and market entry barriers. Strategic moves should prioritize advancing clinical pipelines, securing regulatory approvals, and expanding partnerships.

What Is Aadi Sub's Market Position in Oncology?

Aadi Sub operates mainly in the targeted oncology drug segment, with an emphasis on pancreatic and gastrointestinal cancers. Currently, it has no approved marketed products but advances experimental therapies through early to mid-phase clinical trials.

Competitive Standing

Parameter	Status	Benchmark Comparison
Clinical Trial Phases	Phase 1/2 for lead candidates	Similar to peers like Verseon or Junshi Biosciences
Market Penetration	Limited, mainly research collaborations	Smaller than established players (e.g., Pfizer, Merck)
Patent Portfolio	10+ patent filings for lead compounds	Fewer than top-tier oncology firms
Strategic Collaborations	Partnerships with academic institutions for preclinical research	Fewer than large biotechs with broad alliances

Aadi’s projected entry into the market hinges on demonstrating clinical efficacy alongside regulatory approval timelines.

What Are the Company’s Strengths?

Focused R&D Pipeline

Aadi's pipeline emphasizes proprietary small molecules targeting specific mutations in solid tumors. Its lead agents target pathways like KRAS and TP53, which are valued in oncology.

Intellectual Property

The company holds over 10 patent applications covering novel compounds and formulations. Its patents are primarily filed in the US, Europe, and China through 2025.

Academic and Industry Collaborations

Partnerships with academic centers accelerate early-stage research. These relationships reduce internal R&D costs and provide access to cutting-edge preclinical models.

Strategic Funding

Recent funding rounds raised approximately $75 million, primarily from venture capital and pharmaceutical partners, supporting clinical trial progression and pipeline validation.

What Are the Strategic Challenges?

Clinical Development Risks

Progress through clinical phases remains uncertain. There is no proven clinical efficacy for lead candidates, and delays could impact market entry.

Regulatory Pathways

Getting approval in complex indications like pancreatic cancer requires extensive data. Aadi must align clinical trial design with evolving regulatory expectations, notably in doses, endpoints, and safety profiles.

Competitive Pressure

Major biopharmaceutical firms dominate the market with established therapies. Entering and gaining market share requires demonstrating significant clinical benefit over current standards.

Market Entry Barriers

Pricing negotiations, reimbursement pathways, and patient access influence commercial success. The absence of current FDA or EMA-approved products limits early revenue streams.

What Are Recommendations for Growth and Strategic Alignment?

Accelerate Clinical Trials

Prioritize advancing lead candidates through Phase 2 and Phase 3 trials. Focus on early biomarkers predicting success to optimize resource use.

Strengthen IP and Patent Strategy

Expand patent filings to cover emerging combinations and formulations. Defend IP against potential challenges and extend patent life.

Establish New Collaborations

Seek partnerships for late-stage clinical development, especially with larger players with marketing and distribution capacity.

Explore Market Expansion

Consider targeting oncology indications with higher unmet needs and clearer regulatory pathways, like metastatic colorectal or lung cancers.

Optimize Regulatory Strategy

Engage early with regulatory agencies to align clinical trial design with approval requirements. Prepare for accelerated pathways where applicable.

Key Takeaways

• Aadi Sub has niche presence with focused oncology pipeline but limited market influence.
• Its strengths lie in targeted R&D, strategic academic collaborations, and a growing patent portfolio.
• Clinical development and regulatory pathways remain significant hurdles.
• Growth depends on accelerating clinical trials, expanding partnerships, and robust IP strategies.
• The competitive landscape favors established firms, requiring differentiation through clinical outcomes.

FAQs

1. What is the main therapeutic focus of Aadi Sub?
   It focuses on targeted therapies for pancreatic and gastrointestinal cancers, especially compounds affecting KRAS and TP53 pathways.

2. When might Aadi's drugs reach the market?
   If clinical trials proceed smoothly, regulatory approval could be achievable within 3–5 years post successful Phase 3 trials.

3. How does Aadi compare to larger pharma companies?
   It operates at an earlier development stage with limited market presence. Larger firms have broader pipelines, established products, and extensive commercialization resources.

4. What is the primary challenge for Aadi's commercial success?
   Demonstrating significant clinical efficacy and securing regulatory approval in highly competitive and complex oncology markets.

5. Are there partnership opportunities for Aadi?
   Yes, partnering with larger biopharma firms for late-stage clinical development and commercialization can accelerate growth and market access.

---

Sources

1. Aadi Biosciences Investor Relations. (2023). Corporate Presentation.
2. ClinicalTrials.gov. (2023). Entry details for Aadi pipeline candidates.
3. PatentScope. (2023). Patent filings for Aadi Biosciences.
4. Industry Reports. (2023). Oncology Pipeline Analysis.
5. Market Data. (2023). Oncology Drug Market Size and Competition.